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Abstract
Introduction: Disseminated intravascular coagulation (DIC) is characterized by the concomitant activation of
coagulofibrinolytic disorders and systemic inflammation associated with endothelial dysfunction-induced
microvascular permeability. Angiogenic factors, including vascular endothelial growth factor (VEGF), angiopoietin
(Ang), and their receptors, play crucial roles in angiogenesis and microvascular permeability. The aim of the study
was to assess the relationship between angiogenic factors, their soluble receptors and organ dysfunction
associated with DIC after severe trauma.
Materials and methods: A total of 57 patients with severe trauma were divided into two subgroups; 30 DIC
patients and 27 non-DIC patients. The DIC was diagnosed based on the Japanese Association for Acute Medicine
(JAAM) DIC and the International Society on Thrombosis and Haemostasis (ISTH) overt DIC criteria. The serum levels
of angiogenic factors were measured at the time of admission (Day 1), Day 3 and Day 5. This study compared
levels of these angiogenic factors between the two DIC groups, and evaluated their predictive value for organ
dysfunction.
Results: DIC patients, especially those with ISTH DIC, showed higher Sequential Organ Failure Assessment (SOFA)
scores and lactate levels. There were lower levels of VEGF, Ang1 and the soluble Tie2 in the ISTH DIC patients than
the non-DIC patients. The levels of soluble VEGF receptor-1 (sVEGFR1), Ang2 and the Ang2/Ang1 ratio in the ISTH
DIC patients were higher than in non-DIC patients. The relationship between the presence of massive transfusion
and angiogenic factors indicated the same results. The levels of sVEGFR1, Ang2 and the Ang2/Ang1 ratio correlated
with the SOFA scores. In particular, sVEGFR1 and Ang2 were independent predictors of an increase in the SOFA
score. The lactate levels independently predicted increases in the levels of sVEGFR1 and Ang2. The decrease in the
platelet counts also independently predicted the increase in Ang2 levels in DIC patients.
Conclusions: Angiogenic factors and their soluble receptors, particularly sVEGFR1 and Ang2, are considered to play
pivotal roles in the development of organ dysfunction in DIC associated with severe trauma. DIC-induced tissue
hypoxia and platelet consumption may play crucial roles in inducing sVEGFR1 and Ang2, and in determining the
prognosis of the severity of organ dysfunction.
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Introduction
The survival of trauma patients depends on the ability
to control two opposing conditions, namely, bleeding
during the early phase and thrombosis during the late
phase of trauma [1]. Hess et al. [2] suggested a new
concept regarding the pathophysiological mechanism of
trauma-related hemostatic changes, Acute Coagulopathy
of Trauma-Shock (ACoTS). However, we have pre-
viously demonstrated that this could be best explained
by the development of disseminated intravascular coagu-
lation (DIC) [1,3].
While the activation of the tissue-factor-dependent
pathway at the top of the cascade is the same, DIC is sub-
divided into a fibrinolytic and thrombotic phenotype [3].
DIC at an early phase of trauma, approximately 24 to 48
hours after injury, shows the fibrinolytic phenotype
which affects the patient prognosis due to massive bleed-
ing [1,4]. DIC at a late phase of trauma is a thrombotic
phenotype which also affects the patient prognosis due to
the development of multiple organ dysfunction syndrome
(MODS) [1,3,5].
Vascular endothelial growth factor (VEGF) plays cru-
cial roles in angiogenesis and microvascular permeability
[6]. VEGF mainly binds to two transmembrane receptors,
VEGF receptor-1 (VEGFR1) and VEGFR2. VEGFR2
mainly mediates endothelial growth, survival signals and
pathological angiogenesis. In contrast, VEGFR1-mediated
signaling plays important roles by increasing the vascular
permeability under pathological conditions, such as
ischemia and inflammation.
The angiopoietin (Ang)-Tie2 ligand-receptor system is
restricted to regulation of the endothelium and it is also
involved in multiple organ dysfunction-related pathways
[7]. The Ang-Tie2 system not only regulates angiogen-
esis, but also controls endothelial inflammation, along
with VEGF and its receptor system [8]. Ang1 stabilizes
the endothelial cells, inhibits vascular leakage, and sup-
presses inflammatory and coagulation-related gene
expression through Tie2 activation [8-10]. Ang2 antago-
nizes the binding of Ang1 to Tie2. Therefore, Ang2 is
thought to act as a proinflammatory mediator increasing
fluid leakage through the endothelial vasculature [11].
Several studies have demonstrated that the ratio between
Ang1 to Ang2 better describes the state of activation of
the endothelium, because Ang1 and Ang2 have agonist-
antagonist properties on the endothelium [12,13].
Clinical studies have demonstrated the serum levels of
VEGF to be strongly enhanced after polytrauma and
burn injuries [14]. Ang2 plays a critical role in the patho-
genesis of the activated endothelium with increased vas-
cular permeability observed early after trauma [12].
Moreover, the Ang2 levels in multi-trauma patients are
increased upon the development of septic complications
connected with a poor prognosis [15]. However, no
previous reports have documented the data regarding
these angiogenic factors and their soluble receptors in
DIC associated with severe trauma. This study tested the
hypothesis that the angiogenic factors play pivotal roles
in the development of DIC and DIC-induced organ dys-
function associated with severe trauma. The present
study examined the serial changes in serum angiogenic
factors and their soluble receptors in patients with
trauma-associated DIC and investigated the relationships
between these factors, receptors and organ dysfunction.
Materials and methods
Patients
With the approval of the Institutional Review Board and
after written informed consent was obtained from either
the patients or their kin, severe trauma patients were
enrolled in the study. Severe trauma patients were defined
as those with an Injury Severity Score (ISS) ≥ 9 (at least
one abbreviated Injury Scale ≥ 3) [16]. Patients were
excluded if they were under 18 years of age, had a terminal
illness, were receiving anticoagulant therapy, had known
clotting disorders, such as hematopoietic malignancies or
severe liver cirrhosis, or were complicated with cardiac
arrest. No patients received anticoagulant drugs, such as
heparin, in consideration of re-bleeding during the study
period. In addition, no antifibrinolytic drugs, such as tra-
nexamic acid, were administered because the blood sam-
ples and patients’ information for this study were collected
before publication of another study showing the impor-
tance of early treatment with tranexamic acid in bleeding
trauma patients [17]. Fifteen healthy volunteers served as
the control subjects. The patient source was the same as
that described in our previous study [18].
Definitions
The severity of illness of the patients was evaluated
according to the Acute Physiology and Chronic Health
Evaluation (APACHE) II score at the time of enrollment.
Organ dysfunction was assessed by the Sequential Organ
Failure Assessment (SOFA) score within 24 hr after arrival
at the emergency department (Day 1), as well as on Days 3
and 5. The DIC diagnosis was made on the Japanese Asso-
ciation for Acute Medicine (JAAM) DIC diagnostic criteria
within five days after injury [19]. The overt DIC scores
based on the International Society on Thrombosis and
Hemostasis (ISTH) were also calculated [20]. The fibrin/
fibrinogen degradation product (FDP) was used as the
fibrin-related marker in the ISTH criteria. No increase, a
moderate increase and a strong increase were defined as a
FDP of less than 9, 10 to 24 and more than 25 mg/L,
respectively. When the total score was ≥ 5, a diagnosis
was established by the ISTH criteria. Patients that met
the DIC criteria during the study period were defined as
DIC patients. A massive transfusion was defined as a
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transfusion of more than 10 U (1,400 ml) of packed red
blood cells. The main outcome measure was the 28-day
mortality.
Study protocol and measurement methods
Blood samples were collected by an arterial catheter
within 12 hours after arrival at the emergency depart-
ment (Day 1), as well as on Days 3 and 5. The blood was
immediately placed into individual tubes and centrifuged
at 3,000 rpm, for five minutes at 4°C. The serum and/or
plasma were stored at -80°C until used for the assay.
Serum samples were used for all measurements.
The following variables were measured in duplicate:
VEGF (Quantikene; Human VEGF; R&D Systems, Inc.,
Minneapolis, MN, USA); sVEGFR1 (Quantikene; Human
sVEGF R1/Flt-1; R&D Systems, Inc.), sVEGFR2 (Quanti-
kene; Human sVEGF R2/KDR/Flk-1; R&D Systems, Inc.);
Ang1 (Quantikene; Human Angiopoietin-1; R&D Systems,
Inc.); Ang2 (Quantikene; Human Angiopoietin-2; R&D
Systems, Inc.); and soluble Tie2 receptor (sTie2) (Quanti-
kene; Human Tie-2; R&D Systems, Inc.). The platelet
count, prothrombin time, fibrinogen level, FDP, D-dimer,
and antithrombin were also measured in the patient
plasma to establish the diagnosis and determine the treat-
ment of DIC. In addition, the ABL SYSTEM 620 (Radio-
meter, Copenhagen, Denmark) was used for the lactate
measurement.
A sufficient amount of platelet concentration, fresh fro-
zen plasma (FFP), and packed red blood cells (PRBC) were
transfused, based on repeatedly obtained laboratory data
to maintain the hemodynamics and to treat hemostatic
disorders.
Statistical analysis
The statistical analyses and calculations were performed
with the SPSS 19.0 software package (SPSS, Inc., Chi-
cago, IL, USA). Differences between the two groups
were analyzed using a two-sided nonparametric Mann-
Whitney U test, and categorical variables were com-
pared using Pearson’s chi-square test or Fisher’s exact
test when required. The Kruskal-Wallis analysis of var-
iance was used to compare the three groups. Correla-
tions were evaluated by the Spearman’s rank test.
Multiple regression analyses were undertaken to deter-
mine contributions to SOFA score. The relationship
between the dependent and the independent variables
were analyzed by a multiple regression analysis using
the stepwise method. The results of the regressions
were reported as the partial regression coefficient (B),
95% confidence intervals (CI). The coefficient of deter-
minant (R2) was also reported. A P-value < 0.05 was
considered to be statistically significant. Unless other-




Fifty-seven patients with severe trauma met the inclusion
criteria and were eligible for the present study. Patients
were subdivided into a DIC group (n = 30) or a non-DIC
group (n = 27), based on the JAAM DIC criteria. The
DIC patients were further subdivided into those who met
only the JAAM DIC criteria (JAAM DIC; n = 21) and
those who simultaneously met both the JAAM and ISTH
overt DIC criteria (ISTH overt DIC; n = 9). The baseline
characteristics of the patients are shown in Table 1. The
DIC group had a significantly higher maximal SOFA
score (P < 0.001), although the ISS, APACHE II scores,
P/F ratio and the prevalence of acute respiratory distress
syndrome (ARDS) and sepsis were not significantly dif-
ferent between the DIC and non-DIC groups (ISS, P =
0.394; APACH II score, P = 0.277; P/F ratio, P = 0.194;
ARDS, P = 0.823; sepsis, P = 0.813). The DIC groups
received significantly more blood products (packed red
blood cell, P = 0.001, FFP, P = 0.004, platelet concentrate,
P = 0.032). Table 2 shows the Day 1 data of platelet
counts, coagulation and fibrinolysis factors, and lactate
levels. The higher FDP and D-dimer levels in DIC
patients suggested disseminated fibrin thrombosis.
Serial changes in angiogenic factors and their soluble
receptors
Serial changes in the circulating VEGF, sVEGFR1 and
sVEGFR2 levels are presented in Figure 1. All three groups
showed significantly lower levels of VEGF in comparison
to the controls. In particular, those with the ISTH overt
DIC group showed significantly lower VEGF levels on Day
1 in comparison to non-DIC subjects (P = 0.036).
Although the sVEGFR1 levels on Days 1 and 3 did not dif-
fer between non-DIC and DIC groups, the sVEGFR1 levels
on Day 5 in the ISTH overt DIC group were significantly
higher than those of the non-DIC group (P = 0.004). On
the other hand, the sVEGFR2 levels were not significantly
different between the two groups during the study period.
Figure 2 presents the Ang1, Ang2 and sTie2 levels and the
Ang2/Ang1 ratio. This figure shows that there were signif-
icantly lower levels of Ang1, and higher levels of Ang2 in
the ISTH overt DIC on Day 5 (Ang1, P = 0.026; Ang2, P =
0.038). Therefore, the ratio of Ang2 to Ang1 on Day 5 sig-
nificantly increased in the ISTH overt DIC (P = 0.005). In
addition, the sTie2 levels on Day 1 were lower in the
ISTH overt DIC than those in the non-DIC group (P =
0.010). The patients were subdivided into with and with-
out a massive transfusion. Figure 3 demonstrates the rela-
tionships among angiogenic factors, their soluble receptors
and the presence of massive transfusion. There were sig-
nificantly lower levels of VEGF on Day1, and higher levels
of sVEGFR1 on Day 5 in the massive transfusion group
(VEGF on Day 1, P = 0.022; sVEGFR1 on Day 5, P =
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0.027). Moreover, the Ang2 and the Ang2/Ang1 ratio on
Day 5 significantly increased in the massive transfusion
group (Ang2 on Day 5, P < 0.001, Ang2/Ang1 on Day 5, P
< 0.001). Other angiogenic factors and their receptors
showed no statistical difference during the study period.
Relationships between angiogenic factors, their soluble
receptors and organ dysfunction
Table 3 shows that there were significant positive corre-
lations between the sVEGFR1, Ang2, Ang2/Ang1 and
the SOFA scores in DIC patients. A multiple regression
analysis suggested that sVEGFR1 and Ang2 are indepen-
dent predictors of an increase in the SOFA scores in
DIC patients (Table 4).
Factors influencing the changes in angiogenic factors and
their soluble receptors
A multiple regression analysis was performed to deter-
mine the contributions to sVEGFR1 and Ang2 changes
in DIC patients. Table 5 shows that the maximal lactate
level is an independent predictor of changes in the
sVEGFR1 and Ang2 expression in the DIC patients.
Minimal platelet counts also independently predicted the
increase in the sVEGFR1 levels in patients with DIC.
Discussion
The present study has demonstrated that severe trauma
patients with associated DIC showed significant
decreases in their VEGF, Ang1, and sTie2 levels, and
increases in their SOFA scores, sVEGFR1 and Ang2
levels as well as in the Ang2/Ang1 ratio. sVEGFR1 and
Ang2 were the most prominent predictors of increases
in the SOFA scores in the DIC patients. We also
observed lower levels of VEGF, and higher levels of
sVEGFR1 in the massive transfusion group. In addition,
the Ang2, as well as the Ang2/Ang1 ratio, significantly
increased in the massive transfusion group. However,
massive transfusion was not found to be an independent
Table 1 The baseline clinical characteristics of the patients
DIC P value
Non-DIC JAAM DIC ISTH overt DIC
(n = 27) (n = 21) (n = 9)
Age (years) 50.0 ± 3.7 43.9 ± 4.5 57.2 ± 7.6 0.273
Gender (male/female) 19/8 10/11 4/5 0.192
ISS 26.0 ± 2.7 27.8 ± 2.3 31.7 ± 4.9 0.394
APACHE II score 19.2 ± 1.3 18.0 ± 1.1 24.4 ± 3.6 0.277
SOFA score max 4.5 ± 0.4 5.9 ± 0.5 9.8 ± 1.3 < 0.001
Sepsis (yes/no) 2/25 1/20 1/8 0.813
P/F ratio min 197 ± 21 185 ± 24 134 ± 35 0.194
ARDS (yes/no) 14/13 11/10 6/3 0.823
JAAM DIC max 2.6 ± 0.3 4.9 ± 0.2 6.6 ± 0.44 < 0.001
ISTH DIC max 2.0 ± 0.1 3.4 ± 0.1 5.4 ± 0.2 < 0.001
Packed red blood cell (ml) 491 ± 144 914 ± 174 2436 ± 594 0.001
Massive transfusion (yes/no) 3/24 5/16 5/4 0.026
FFP (ml) 445 ± 148 1032 ± 429 2503 ± 1011 0.004
Platelet concentrate (U) 3.5 ± 8.9 7.4 ± 3.2 26.7 ± 12.4 0.032
Outcome (survived/died) 26/1 20/1 6/3 0.029
DIC, disseminated intravascular coagulation; ISS, Injury Severity Score; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure
Assessment; MODS, multiple organ dysfunction syndrome; JAAM, Japan Association for Acute Medicine; ISTH, International Society on Thrombosis and
Haemostasis; FFP, fresh frozen plasma. We defined the maximum or minimum score as the highest or lowest score on day1, day3 and day5, when we collected
the patient data and samples. Packed red blood cells, FFP, and Platelet concentrate indicate the total volume within 5 days after injury.
Table 2 The platelet counts, coagulation and fibrinolysis factors, and lactate levels on day1
DIC p value
Non-DIC JAAM DIC ISTH overt DIC
Platelet counts (109/L) 153.4 ± 12.3 141.1 ± 11.9 110.0 ± 27.0 0.295
Prothrombin time (sec) 13.0 ± 0.3 13.7 ± 0.3 17.9 ± 1.3 < 0.001
Fibrinogen (g/L) 2.46 ± 0.19 1.88 ± 0.13 1.04 ± 0.06 < 0.001
FDP (mg/L) 19.1 ± 4.0 55.0 ± 7.9 150.6 ± 55.6 < 0.001
D-dimer (μg/mL) 30.6 ± 10.5 32.4 ± 5.6 79.7 ± 21.8 0.004
Antithrombin (%) 77.8 ± 3.5 71.7 ± 3.3 59.0 ± 8.0 0.014
Lactate (mmol/L) 2.9 ± 0.3 4.3 ± 0.7 6.8 ± 1.8 0.010
The abbreviations are same as Table 1. FDP, fibrin/fibrinogen degradation products.
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factor for predicting the SOFA scores in the multivari-
able analysis.
Previous studies have demonstrated the JAAM DIC
diagnostic criteria to have an acceptable validity for the
diagnosis of DIC at an early phase of trauma, and JAAM
DIC exists along with a continuum to ISTH overt DIC
[4,21]. In addition, we previously reported that DIC at an
early phase of trauma, which was based on the JAAM
DIC criteria and ISTH DIC criteria, continuously
Figure 1 The levels of VEGF, sVEGFR1 and sVEGFR2 in the
serum. White bars, control subjects; Hatched bars, non-DIC patients;
Gray bars, JAAM DIC patients; Black bars, ISTH DIC patients.
Figure 2 The levels of Ang1, Ang2, sTie2 and the ratio of
Ang2/Ang1 in the serum. White bars, control subjects; Hatched
bars, non-DIC patients; Gray bars, JAAM DIC patients; Black bars,
ISTH DIC patients.
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progressed to DIC at a late phase until five or six days
after the trauma [22].
Major trauma causes massive tissue injury, and initiates
a systemic inflammatory response syndrome. Endothelial
activation and dysfunction play a major role in the devel-
opment of organ injuries after trauma [23]. Angiogenic
factors, such as VEGF, angiopoietin and their receptors,
have complex effects on endothelial cells [6,7].
Grad et al. [14] demonstrated that the serum VEGF
levels in trauma and burn patients with complications,
such as sepsis, ARDS or multiple organ dysfunction syn-
drome (MODS), are lower than those of the patients
without such complications. Lower VEGF levels are also
associated with organ dysfunction and a poor outcome in
patients with sepsis [24,25]. The current results were
consistent with these studies. However, several studies
have reported that the plasma VEGF levels in the patients
with septic shock are higher than those of patients with-
out shock, and that the VEGF concentration at the time
of admission correlates with the severity of disease
[26,27]. Therefore, the levels of VEGF in patients with
sepsis, septic shock and other critical illnesses remain
controversial [12,28]. The present study measured the
VEGF levels using serum samples. Webb et al. [29] sug-
gested that plasma is the preferred medium to measure
VEGF because the platelet-mediated secretion of VEGF
during the clotting process could artificially increase the
levels of VEGF. Furthermore, this study indicated that
the coexistence of sVEGFR1 reduces the detection of
Figure 3 The levels of VEGF, sVEGFR1, Ang2 and the ratio of
Ang2/Ang1 in the serum. White bars, control subjects; Hatched
bars, without massive transfusion group; Gray bars, with massive
transfusion group.
Table 3 Spearman’s correlation between the angiogenic






SOFA-Ang2 0.389 < 0.001
SOFA-Ang2/Ang1 0.233 0.035
SOFA-sTie2 0.017 0.882
Table 4 The results of the multiple regression analysis
using a stepwise method for prediction of the maximum
of SOFA score in DIC patients
B SE b P value 95% CI
sVEGFR1 max 0.004 0.001 0.460 0.007 0.001-0.006
Ang2 max 0.000 0.000 0.411 0.014 0.000-0.000
R2 = 0.630, ANOVA P < 0.001
B, partial regression coefficient; SE, standard error; ß, standard partial
regression coefficient; CI, confidence interval; R2, coefficient of determinant;
ANOVA, analysis of variance. Peak and nadir values of all angiogenic factors
and their soluble receptors, were defined respectively as the maximal and
minimal levels measured for each patient during the course of data collection.
Potential predictor variables included the presence of massive transfusion, all
peak and nadir values of all angiogenic factors and their receptors.
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VEGF. Platelets are one of the main transporters of circu-
lating VEGF, and thrombin-activated platelets release
VEGF [30,31]. We observed a significant correlation
between the platelet counts and VEGF levels, and marked
increases in the levels of sVEGFR1 in DIC patients with
sepsis (our unpublished data; S Jesmin, T Wada,
S Gando, et al.). Therefore, we believe that the decrease
in the platelet counts and the elevation of sVEGFR1 are
the main causes of lower VEGF levels. We showed a sig-
nificant correlation between the VEGF and sVEGFR1
levels (Spearman rho = -0.236, P = 0.003, n = 150), but
no correlation was observed between the platelet counts
and VEGF in the present study. The precise mechanism
of lower VEGF levels remains unclear; however, we spec-
ulate that the increase in the sVEGFR1 levels may be one
of the causes of the lower VEGF levels in severe trauma
patients, especially in those with DIC.
The present study found the sVEGFR1 levels in the
ISTH overt DIC patients to be significantly higher than
those of the non-DIC patients on Day 5 and sVEGFR1
was an independent predictor of the increase in the
SOFA scores in patients with DIC associated with severe
trauma. sVEGFR1 is generated by alternative splicing of
VEGFR1 mRNA and functions as a decoy molecule, com-
peting with VEGFR1 for binding to VEGF [27]. VEGF
and VEGFR1 on the cell surface are up-regulated after
endothelial injury, promoting re-endothelialization by the
enhancement of vascular remodeling [32]. The results
suggest that higher sVEGFR1 levels may hamper VEGF
signaling in the process of endothelial repair, thereby
leading to disease progression and organ dysfunction
[28,33]. Furthermore, high circulating sVRGFR1 levels
have been reported to correlate with morbidity and mor-
tality, and are a potent marker of disease severity in sep-
tic or critically ill patients [27,28,34]. The current results
were in agreement with these previous studies. On the
other hand, an in vivo study suggested that VEGFR1 is
involved in the migration of monocytes/macrophages,
and that elevation of sVEGFR1 leads to an anti-inflam-
matory state [28,35]. The present results and the previous
studies indicate that sVEGFR1 may have dual roles in the
inflammatory processes, being involved in both endothe-
lial cell damage and in inducing an anti-inflammatory
effect. However, the inflammation caused by the high
sVEGFR1 level may overcome its anti-inflammatory
effects, leading to organ dysfunction in patients with DIC
associated with trauma.
sVRGFR2 is a soluble truncated form of VEGFR2. Like
sVEGFR1, sVEGFR2 may have regulatory consequences
with respect to VEGF-mediated angiogenesis. However,
its precise role has not yet been clarified [36]. The pre-
sent study found no significant differences in the levels
of sVEGFR2 between the DIC group and non-DIC
group, thus suggesting that it does not have a major
role in DIC after severe trauma.
Previous studies indicated that the serum levels of
Ang2 are related to poor prognosis, and are indepen-
dently correlated with the severity of injury and tissue
hypoperfusion in multi-trauma patients [12,15]. Other
studies also show that lower Ang1 and higher Ang2
levels are associated with a poor outcome in patients
with sepsis or critical illness [9,24,37,38]. Ang1 has anti-
inflammatory properties and protects against vascular
leakage, while Ang2 promotes inflammation and
increases the vascular permeability, leading to the devel-
opment of ARDS [8,9,39,40]. Moreover, positive rela-
tionships between Ang2 and inflammatory cytokines,
such as TNF-alpha and IL-6, have been observed [37].
These results suggest that elevations in Ang2 and a
decrease in Ang1 may reflect a pro-inflammatory state,
and that this is best summarized by the ratio between
Ang1 and Ang2 [12,13]. The current study and previous
studies suggest that a higher Ang2 level, as well as an
imbalance of Ang1 and Ang2 (high Ang2/Ang1 ratio),
are both associated with inflammation during DIC asso-
ciated with severe trauma, thus resulting in organ dys-
function. We observed that DIC associated with sepsis
has lower levels of Ang1 and higher levels of Ang2 on
Day 1 (our unpublished data; S Jesmin, T Wada, S
Gando, et al.). The present study showed that the same
changes could be found on Day 5, when the fibrinolytic
DIC proceeded into thrombotic DIC, which is accentu-
ated in sepsis. These results suggest that the changes in
the Ang levels may, therefore, play some role in the
development of thrombotic DIC. Furthermore, the
administration of Ang1 protects the vasculature from
leakage, countering the potentially lethal actions of
VEGF and inflammatory agents in animal experiment
[41]. The correction of the imbalance between Ang1
and Ang2 by administration of Ang1 or inhibition of
Ang2 may represent a new therapeutic target for severe
inflammatory illnesses, such as DIC related to trauma.
Table 5 The result of the multiple regression analysis
with stepwise method for prediction of sVEGFR1 and
Ang2 in DIC patients
B SE b P value 95% CI
sVEGFR1
Lactate max 49.1 15.8 .464 0.004 16.65-81.52
Platelet min -33.2 13.4 -0.372 0.019 -60.6- -5.794
Ang2
Lactate max 1080.2 218.7 0.682 < 0.001 632.2-1528.1
sVEGFR1; R2 = 0.491, ANOVA P < 0.001
Ang2; R2 = 0.466, ANOVA P < 0.001
The abbreviations are same as Table 4.
Potential predictor variables included the peak prothrombin time, FDP, D-
dimer, and lactate levels and nadir platelet counts, fibrinogen and
antithrombin during the course of data collection.
Wada et al. Critical Care 2012, 16:R63
http://ccforum.com/content/16/2/R63
Page 7 of 10
Soluble Tie2 (sTie2) is released by proteolytic cleavage
of the extracellular domain by matrix metalloproteases,
which occurs constitutively or after VEGF signaling [42].
Cleaved sTie2 binds to both Ang1 and Ang2 to inhibit
ligand-mediated Tie2 receptor activation and down-
stream signaling [43]. A previous study also showed that
the sTie2 levels correlate with the VEGF levels, support-
ing the in vivo shedding of Tie2 through VEGF signaling
[44]. The sTie2 levels on Day 1, as well as the VEGF
levels, were significantly lower in the ISTH overt DIC
patients than in the non-DIC patients in the current ser-
ies. This result coincided with those of previous studies.
Yuan et al. [45] reported that Ang2 binds sTie2 with
approximately 20-fold lower affinity than Ang1 does.
Therefore, sTie2 may sift the Ang2/Ang1 in favor of
Ang2. The present study found the sTie2 levels in ISTH
DIC on Day 1 to be lower than those in non-DIC, but
no significant difference was observed between the two
groups on Day 5. The changes in the Ang1 and Ang2
levels in the ISTH DIC group on Day 5 may be affected
by the augmentation of the sTie2 activity. These results
and the previous studies may indicate that there is a
close relationship between the VEGF/VEGFR signaling
pathway and the Ang/Tie2 signaling system.
DIC patients in the current study showed higher levels
of FDP, D-dimer and lactate, indicating tissue hypoxia
induced by disseminated fibrin thrombosis. A multiple
regression analysis also showed that lactate and platelet
were independent predictors of an increase in the
sVEGFR1 levels in DIC patients. DIC is characterized by
the widespread activation of tissue factor, massive
thrombin generation and fibrin formation, leading to
microvascular occlusion and tissue hypoxia [46]. Any
type of shock can precipitate DIC in response to tissue
hypoxia, slow capillary flow, and endothelial damage [1].
Tissue hypoxia transcriptionally induces the expression
of VEGFR1 [47]. In addition, a decrease in the platelet
counts may correlate with the lower VEGF levels, lead-
ing to the elevation of sVEGFR1. These results indicate
that DIC-induced tissue hypoxia and platelet consump-
tion may play pivotal roles in inducing an alternatively
spliced form of VEGFR1, sVEGFR1, in patients with
DIC associated with severe trauma. The Ang2 levels of
the DIC patients were also independently predicted by
lactate. Inflammatory cytokines are thought to be stimuli
for Ang2 production in the clinical setting [37]. The
results of the current study suggest that DIC-induced
tissue hypoxia is another major determination of circu-
lating Ang2 in the same way as in the experimental
study [48]. Therefore, DIC is considered to be closely
involved in the pathogenesis of organ dysfunction after
trauma. Further studies in a larger number of subjects
in a more diverse population are thus needed to confirm
the roles and clinical relevance of angiogenic factors,
their receptors and the occurrence of DIC associated
with severe trauma.
Conclusions
This study demonstrated that there were lower serum
levels of VEGF, Ang1, and higher sVEGFR1 and Ang2
levels, and an increased Ang2/Ang1 ratio in patients
with ISTH overt DIC associated with severe trauma. We
also observed lower levels of VEGF, and higher levels of
sVEGFR1 in the massive transfusion group. In addition,
the Ang2 as well as the Ang2/Ang1 ratio significantly
increased in the massive transfusion group. The changes
in sVEGFR1, Ang2 and the Ang2/Ang1 ratio changes
were significantly correlated with the SOFA scores in
DIC patients. In particular, sVEGFR1 and Ang2 were
found to be independent predictors of an increase in the
SOFA scores in DIC patients. Moreover, the maximum
lactate levels and the minimum platelet counts indepen-
dently predicted increases in the sVEGFR1 levels. These
data, therefore, support the pathophysiological relation-
ship between organ dysfunction in patients with DIC
associated with severe trauma and angiogenic factors
and their receptors.
Key messages
• There are significant positive correlations among
sVEGFR1, Ang2, Ang2/Ang1 ratio, and the SOFA
scores in the trauma patients with DIC.
• sVEGFR1 and Ang2 are independent predictors of
an increase in the SOFA scores in DIC trauma
patients.
• The maximum lactate levels and the minimum pla-
telet counts independently predicted increases in the
sVEGFR1 levels.
• Lactate also independently predicts the Ang2 levels
of the DIC patients.
• These changes are most prominent in patients with
ISTH overt DIC.
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